• TRADE NAME: Nucala (GSK)
• INDICATIONS: Adjunctive treatment for severe eosinophilic asthma
  
• CLASS: Interleukin-5 antagonist, Monoclonal antibody
• HALF-LIFE: 16–22 days

• FDA APPROVAL DATE: 11/04/2015
• CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
  None known
• PREGNANCY: Insufficent evidence to inform drug-associated risk

• See adverse reactions attributed to class:

  Interleukin-5 antagonist

  Monoclonal antibody

DRUG REVIEW ARTICLE

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of mepolizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.

(Note that non-subscribers to the journal will only be able to see an abstract of the article.)